Michael Franti

Michael Franti

Company: Boehringer Ingelheim

Job title: Director & Head of Regenerative Medicine, Viral Platform, Drug Metabolism & Pharmacokinetics


Pre-Clinical PK, BD, & Immunogenicity Studies to Support FIM Studies with Vesicular Stomatitis Virus – Glycoprotein (VSV-GP) 10:30 am

Strategies and approaches employed to bring Vesicular Stomatitis Virus pseudotyped with LCMV glycoprotein (VSV-GP) through IND-enabling tox/biodistribution studies to enable first-in-man trials More specifically, novel molecular toolset to capture time course of viral replication, understand the unique PK, analyze shedding, vector persistence, assess the time course kinetics of immune responses after both intravenous and intratumoral…Read more

day: Pre-Conference Day

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.